PARIS--(BUSINESS WIRE)--Neovacs, a biotechnology company developing proprietary immunotherapies for autoimmune and chronic diseases, today announced the initiation of a Phase IIa clinical study of its TNFa Kinoid immunotherapy in rheumatoid arthritis patients who have ceased to respond to an anti-TNFa monoclonal antibody and who test positive for anti-drug antibodies (ADAs). The announcement follows trial clearance by the French regulatory authority (AFFSAPS) and the central ethics committee. Neovacs has also submitted the trial protocol to the relevant authorities in two other European countries and has already received regulatory clearance in one and ethics committee approval in the other.
